BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 10634677)

  • 1. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches.
    J Card Fail; 1999 Dec; 5(4):357-82. PubMed ID: 10634677
    [No Abstract]   [Full Text] [Related]  

  • 2. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America.
    Pharmacotherapy; 2000 May; 20(5):495-522. PubMed ID: 10809338
    [No Abstract]   [Full Text] [Related]  

  • 3. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From left ventricular dysfunction to heart failure.
    Cleland JG
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11):1397-402. PubMed ID: 9092398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure: recent advances in prevention and treatment.
    Fonarow GC
    Rev Cardiovasc Med; 2000; 1(1):25-33, 54. PubMed ID: 12457149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.
    Thornton PL; Ahmed A
    J Am Coll Cardiol; 2004 Apr; 43(7):1333; author reply 1333-4. PubMed ID: 15063454
    [No Abstract]   [Full Text] [Related]  

  • 8. [The defibrillator is not a comprehensive healing method].
    Stiefelhagen P
    MMW Fortschr Med; 2006 Aug; 148(31-32):14. PubMed ID: 16938917
    [No Abstract]   [Full Text] [Related]  

  • 9. Caring for patients with heart failure.
    Svendsen A; Arnold JM; Parker J;
    Can Nurse; 2006 Mar; 102(3):14-5, 17. PubMed ID: 16579216
    [No Abstract]   [Full Text] [Related]  

  • 10. Sudden cardiac death after heart failure; symptomatic versus disease treatment? An editorial comment.
    Buckberg GD;
    Heart Fail Rev; 2004 Oct; 9(4):347-51. PubMed ID: 15886980
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic left heart failure. A focus on the pathogenetic basis of medical treatment].
    Novosel MK; Haghfelt TH
    Ugeskr Laeger; 2006 May; 168(19):1854-6. PubMed ID: 16756801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction.
    Goldberg LR; Jessup M
    Circulation; 2006 Jun; 113(24):2851-60. PubMed ID: 16785351
    [No Abstract]   [Full Text] [Related]  

  • 13. The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
    Porcu M
    Ital Heart J; 2002 Jul; 3(7):437-8. PubMed ID: 12189976
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis and management of diastolic dysfunction and heart failure.
    Satpathy C; Mishra TK; Satpathy R; Satpathy HK; Barone E
    Am Fam Physician; 2006 Mar; 73(5):841-6. PubMed ID: 16529092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of neurohormonal modulators in heart failure with relatively preserved systolic function.
    Rapp JA; Gheorghiade M
    Heart Fail Clin; 2005 Apr; 1(1):77-93. PubMed ID: 17386836
    [No Abstract]   [Full Text] [Related]  

  • 17. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure.
    Liu P; Arnold M; Belenkie I; Howlett J; Huckell V; Ignazewski A; LeBlanc MH; McKelvie R; Niznick J; Parker JD; Rao V; Ross H; Roy D; Smith S; Sussex B; Teo K; Tsuyuki R; White M; Beanlands D; Bernstein V; Davies R; Issac D; Johnstone D; Lee H; Moe G; Newton G; Pflugfelder P; Roth S; Rouleau J; Yusuf S;
    Can J Cardiol; 2001 Dec; 17 Suppl E():5E-25E. PubMed ID: 11773943
    [No Abstract]   [Full Text] [Related]  

  • 18. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
    Norgard NB; Stark JE
    Pharmacotherapy; 2008 Jul; 28(7):920-31. PubMed ID: 18576907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment.
    Chavey WE; Blaum CS; Bleske BE; Harrison RV; Kesterson S; Nicklas JM;
    Am Fam Physician; 2001 Sep; 64(6):1045-54. PubMed ID: 11578026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.